Tony Moly sold its stake of AtoGEN (CEO Kang Ji-hee), a subsidiary bio-venture company that researches and develops microbiome treatments. Tony Moly announced on the 15th that it has disposed of about 338,800 shares of AtoGen for 7 billion won to Yuhan Corporation.
Through this stake sale, Tony Moly improved its financial structure by gaining a profit margin of about 4 billion won.
※For more information on this article, please contact The K Beauty Science. We offer it for free of charge, and only for those who request it. Contact: firstname.lastname@example.org